On July 26, Matthew Holman, the director of the Office of Science at the Food and Drug Administration’s Center for Tobacco Products (CTP), told staff that he would be leaving his role for an undisclosed position at Philip Morris International (PMI).
Brian King, who became CTP’s director in early July, wrote in a letter to colleagues that Holman would be departing “effective immediately,” revealing that the former OS head “has been on leave since before my tenure began at the Center” and saying that “he recused himself, consistent with agency ethics policies, from all CTP/FDA work while exploring career opportunities outside of government.”
“FDA thanks Dr. Holman for his federal service and wishes him well,” an agency spokesperson said in a statement to Filter. “The work of the Center for Tobacco Products’ Office of Science is essential to our mission to protect Americans from tobacco-related disease and death. We are confident in the expertise and ability of our staff to continue this critical public health work while the Center for Tobacco Products conducts a nationwide search to identify the next Director for the Office of Science.”
Alex Norcia – Filter – 2022-07-27
Want More Investigative Content?
